Abstract 225P
Background
Common evolution of non-muscle invasive bladder cancer (NMIBC) is local recurrence or progression to muscle invasive bladder cancer (MIBC). Some patients (pts) with NMIBC might develop metastases without progression to MIBC. Clinical evolution of these atypical presentations is unknown. Bladder cancer over the last 5 years has surged by over 13% in India. 50-70% of NMIBC cases recur, and around 10-20% progress to MIBC. Challenge in treatment is identifying the patients with mutations or gene expression patterns for targeted therapy, which is not feasible for all owing to high cost. While omics categorized Western patients, molecular landscape of Indian NMIBC remains incomplete. Herein we report a potential predictive signature, derived by combining transcriptome and whole exome sequencing data of a cohort of NMIBC patients treated in our centre.
Methods
From 2018 to 2021, 25 pts treated at our centre were included for the study, which has been approved by Institutional Ethics committee. Median age at diagnosis was 64Y. 88% received intravesical BCG. 60% were T1 stage and recurrence rate 48%. RNA sequencing and whole exome sequencing were performed on 25 primary NMBIC tumors. Machine learning model was used to predict recurrence status. Mutational status between recurrent and non-recurrent patients was also obtained. The gene expression signature was validated in external datasets including GSE13507 and GSE154261.
Results
435 genes were differentially expressed between recurred and non-recurred patients (p<0.05). Machine learning model predicted recurrence with 90% accuracy. Top pathways upregulated include signalling by nuclear receptors, Shigellosis etc. Downregulated include cell adhesion, PIK-AKT, and ECM reorganization. Validation in external dataset correlated positively with p<0.05. In addition to most previously reported signatures and APOBEC, we also found mutations in FGFR3, ABC transporters, and DAMP, differentially regulated between recurred vs non recurred patients.
Conclusions
We identified novel differentially regulated genes and mutations in genes that predicts recurrence with 90% accuracy. Further analysis in a larger set is underway to complete the validation of the predictive model.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Sri Shankara Cancer Hospital and Research Center.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
87TiP - Phase I expansion study of the tissue factor (TF)–targeting antibody-drug conjugate (ADC) XB002 as a single-agent and combination therapy in patients with advanced solid tumors (JEWEL-101)
Presenter: Mustafa Syed
Session: Poster Display
Resources:
Abstract
88TiP - A phase Ib study of HMBD-001, a monoclonal antibody targeting HER3, with or without chemotherapy in patients with genetic aberrations in HER3 signaling
Presenter: Nick Pavlakis
Session: Poster Display
Resources:
Abstract
93P - Efficacy and safety of fruquintinib (F) + best supportive care (BSC) vs placebo (P) + BSC in refractory metastatic colorectal cancer (mCRC): Asian vs non-Asian outcomes in FRESCO-2
Presenter: Daisuke Kotani
Session: Poster Display
Resources:
Abstract
94P - Sidedness-dependent prognostic impact of gene alterations in metastatic colorectal cancer in the nationwide cancer genome screening project in Japan (SCRUM-Japan GI-SCREEN)
Presenter: Takeshi Kajiwara
Session: Poster Display
Resources:
Abstract
95P - Interim results of a prospective randomized controlled study to compare the clinical outcomes of total neoadjuvant therapy vs long course chemoradiotherapy in locally advanced carcinoma rectum
Presenter: Sandip Barik
Session: Poster Display
Resources:
Abstract
96P - Tyrosine kinase inhibitor (TKI) plus PD-1 blockade in TKI-responsive MSS/pMMR metastatic colorectal adenocarcinoma (mCRC): Updated results of TRAP study
Presenter: Jingdong Zhang
Session: Poster Display
Resources:
Abstract
97P - Asian subgroup analysis of the phase III LEAP-017 trial of lenvatinib plus pembrolizumab vs standard-of-care in previously treated metastatic colorectal cancer (mCRC)
Presenter: Rui-Hua Xu
Session: Poster Display
Resources:
Abstract
98P - Real clinical impact of postoperative surgical complications after colon cancer surgery
Presenter: Toru Aoyama
Session: Poster Display
Resources:
Abstract
99P - Extended lymphadenectomy may not be necessary for MSI-H colon cancer patients after immunotherapy
Presenter: Rongxin Zhang
Session: Poster Display
Resources:
Abstract
100P - Identification of phenomic data in the pathogenesis of colorectal cancer: A UK biobank data analysis
Presenter: Shirin Hui Tan
Session: Poster Display
Resources:
Abstract